For adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, the recommended dose is 50 mg once a week injected under the skin. For adults with plaque psoriasis, the initial recommended dose is 50 mg twice weekly (3 or 4 days apart) injected under the skin.

BRENZYS is a medicine for treating people with moderate to severe forms of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and a type of disease called psoriatic (sore-ee-ah-tick) …

Based on Health Canada’s review, the benefit/risk profile of Brenzys is favourable for: treatment of moderately to severely active rheumatoid arthritis (RA) in adults. Treatment is effective in reducing the signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function.

SB4 (Benepali™ or Brenzys ®, Samsung Bioepis) was the first etanercept biosimilar to demonstrate equivalent efficacy and pharmacokinetics and comparable safety to its reference product (Enbrel, Pfizer; Enbrel is a trademark of Wyeth LLC) in clinical trials [3, 4].

BRENZYS (etanercept) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumour necrosis factor receptor (TNFR) linked to the Fc portion of human immunoglobulin (IgG1).

此次批准，使Brenzys成为加拿大卫生部批准的首个皮下注射抗肿瘤坏死因子（anti-TNF）生物仿制药，该药也是默沙东与三星Bioepis生物仿制药合作协议中首个获加拿大卫生部批准的产品。

Brenzys (etanercept) is a biologic medicine that helps the pain and swelling of arthritis. It is used in the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and other types of arthritis.

2025年1月7日 · Adults with Psoriatic Arthritis (PsA): Brenzys is used for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Brenzys can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone.

Etanercept is used on the PBS to treat severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, severe chronic plaque psoriasis and severe active juvenile idiopathic arthritis (Brenzys is available for these indications, with the exception of severe active juvenile idiopathic arthritis).

2024年4月1日 · Brenzys ® contains the active ingredient etanercept. Etanercept is a biotechnology-derived protein that works by binding to and inactivating Tumour Necrosis Factor (TNF), a naturally occurring chemical in your bloodstream that contributes to …